Kantar Health Blog

  • Stephanie Hawthorne
    Oncology Conference Insight: ASH 2014 --- Proteasome inhibitors and immunomodulators (IMiDs) are the mainstay of therapy for multiple myeloma. For years, treatment has relied on Velcade® (bortezomib, Millennium/Takeda/Johnson & Johnson) and Revlimid® (lenalidomide, Celgene) as part of first-line and second-line therapy, usually in sequence. Recently, two advances have changed this paradigm.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ESMO 2014 --- The role of Programmed Death-1 (PD-1) pathway in suppression of antitumor immunity has become one of the hottest topics in oncology over the past couple of years. PD-1 is a key immune checkpoint receptor expressed on activated T-cells, and binding of PD-1 to its ligand (PD-L1) results in the suppression of the immune response. While the PD-1 pathway normally plays a protective role by attenuating immune-mediated destruction of healthy tissue, the pathway can be exploited by cancer cells to protect themselves from the attack by tumor-specific T-cells.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ESMO 2014 --- Head and neck cancer patients tend to receive chemotherapy doublets with or without the only approved targeted agent, the EGFR antibody Erbitux® (cetuximab, Bristol-Myers Squibb/Lilly/Merck Serono) as first-line therapy. Up to 90% of squamous cell carcinoma of the head and neck (SCCHN) patients have a tumor with EGFR aberrations, and according to Kantar Health’s CancerMPact® Treatment Architecture United States, in 2013 38% of chemotherapy-naïve SCCHN patients received Erbitux as part of their first-line therapy for advanced disease.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ESMO 2014 --- The introduction of Herceptin® (trastuzumab, Roche/Genentech) over a decade ago turned HER2+ metastatic breast cancer (MBC) from what was once a patient population with poor prognosis to one with a vastly improved outlook and led the way for an influx of targeted therapies for this population. Now, the armamentarium against HER2+ MBC has expanded and includes several HER2-targeted agents: Tykerb® (lapatinib, GSK), Perjeta® (pertuzumab, Roche/Genentech) and Kadcyla® (ado-trastuzumab, Roche/Genentech).
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    New biomarker data in metastatic colorectal cancer (mCRC) presented at ASCO 2014 showed clinical implications of RAS mutations. The influence of RAS mutations on testing and treatment patterns of mCRC has profound implications on a tumor’s behavior throughout the course of the disease.
    Continue Reading > | Go comment! | Share